Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

993
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
993
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.7K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

9.3K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.3K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

566
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
566
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Copper-catalyzed three-component thiocyanosulfonylation of allenes.

Chemical communications (Cambridge, England)·2026
Same author

Toxicological Evaluation of Vanillin Flavor in E-Liquid Aerosols on Endothelial Cell Function: Findings from the Replica Project.

Cardiovascular toxicology·2026
Same author

Characterization and comparison of structured and unstructured electronic health record data mapped to MedDRA for post-marketing surveillance.

JAMIA open·2026
Same author

Agreement between Surveillance, Epidemiology, and End Results- and Medicare Claims-Derived Uterine Cancer Treatment Data.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

New Measurements of the Deuteron-to-Proton F_{2} Structure-Function Ratio.

Physical review letters·2025
Same author

A Dose-Aware Model for Revealing Dose-Risk Relationship of Drug-Drug Interaction.

CPT: pharmacometrics & systems pharmacology·2025
Same journal

Effectiveness of Metformin in Preventing Colorectal Cancer Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation.

Pharmacoepidemiology and drug safety·2026
Same journal

Trends in Pharmacist-Prescribed Dispensing Records of HIV Pre-Exposure (2020-2025) and Post-Exposure Prophylaxis (2020-2024) in Brazil: A Time Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

French Consumption of Methylphenidate in Primary Care From 2016 to 2023, Impact of Prescribing Policy Changes-A Time-Series Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study.

Pharmacoepidemiology and drug safety·2026
Same journal

Comparative Effectiveness of Oral Fluoropyrimidines Versus FOLFOX as Adjuvant Therapy for Stage III Colon Cancer: A Retrospective Cohort Study Using Overlap-Weighted Restricted Mean Survival Time Analysis.

Pharmacoepidemiology and drug safety·2026
Same journal

Association Between EGFR-TKI-Associated Skin Rash and Recorded Mortality in Non-Small Cell Lung Cancer: A Real-World Analysis Accounting for Immortal Time Bias.

Pharmacoepidemiology and drug safety·2026
See all related articles

Related Experiment Video

Updated: Sep 11, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K

Potential Drug Dose-Specific Adverse Three-Drug Combinations: A US Insurance Claims Data-Based Study.

Y Shi1, A Sun1, C W Chiang2

  • 1Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA.

Pharmacoepidemiology and Drug Safety
|August 18, 2025
PubMed
Summary
This summary is machine-generated.

The study identified over 500 adverse three-drug combinations. Reducing drug doses, even without discontinuation, lowered the risk of adverse drug events (ADEs) for many combinations.

Keywords:
adverse drug eventsdosedrug combinationpharmacoepidemiologytoxicity

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Related Experiment Videos

Last Updated: Sep 11, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Area of Science:

  • Pharmacovigilance
  • Pharmacoepidemiology
  • Drug Safety

Background:

  • Three-drug combination use is rising, increasing the risk of adverse drug events (ADEs).
  • Previous studies identified potential adverse combinations, but dose-risk relationships remain unclear.

Purpose of the Study:

  • To investigate the relationship between drug dosage in three-drug combinations and the risk of ADEs.
  • To explore if reducing drug doses can mitigate ADE risk.

Main Methods:

  • Utilized matched case-control datasets from US health insurance claims.
  • Employed conditional logistic regression to analyze dose-ADE risk.
  • Applied Benjamini and Hochberg's procedure for false discovery rate (FDR) control.

Main Results:

  • Identified over 500 potential adverse three-drug combinations (OR ≥ 1.3, FDR < 0.05).
  • Decreasing the dose of one drug reduced ADE risk in 74% of combinations compared to high-dose regimens.
  • Dose reduction was effective without requiring drug discontinuation (p < 0.05).

Conclusions:

  • Specific three-drug combinations significantly increase ADE risk.
  • Drug dosage is a key factor in assessing ADE risk for many combinations.
  • Dose adjustment offers a viable strategy to reduce ADEs from combination therapies.